Chu, Shuk Han,
Zhao, Xu,
Komber, Ahmad,
Cheyne, Joshua,
Wu, Simiao,
Cowey, Eileen,
Kutlubaev, Mansur,
Mead, Gillian (2023) by
drug type and sensitivity analysis after excluding the trials at high risk of bias. Secondary outcomes
Sufianov, Albert,
Beilerli, Aferin,
Kudriashov, Valentin,
Ilyasova, Tatiana,
Wenjie, Bu,
Beylerli, Ozal (2023) of therapeutic biomolecules to their target is a challenging issue, which can be solved by innovations in
drugRodkin, Stanislav,
Nwosu, Chizaram,
Raevskaya, Margarita,
Khanukaev, Maxim,
Bekova, Khava,
Vasilieva, Inna,
Vishnyak, Diana,
Tolmacheva, Anastasia,
Efremova, Elena,
Gasanov, Mitkhat,
Tyurin, Anton (2023) . To date, there are no clinically effective neuroprotective
drugs. In this study, we examined the role
Beylerli, Ozal,
Tamrazov, Rasim,
Gareev, Ilgiz,
Ilyasova, Tatiana,
Shumadalova, Alina,
Bai, Yunlong,
Yang, Baofeng (2023) the brain parenchyma makes them attractive candidates for non-invasive biomarkers and
drug delivery systems